Hematological disorders after salvage <scp>PARPi</scp> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes-Reference-Cited by-同舟云学术

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Published:2022-07-02 Issue:10 Volume:151 Page:1791-1803
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Todisco Elisabetta¹²,Gigli Federica¹,Ronchini Chiara³^ORCID,Amato Viviana¹,Sammassimo Simona¹,Pastano Rocco¹,Parma Gabriella⁴,Lapresa Maria Teresa⁴,Bertolini Francesco⁵^ORCID,Corsini Chiara⁵,Gregato Giuliana⁵,Poletti Claudia⁵,Pelicci Pier Giuseppe⁶⁷,Alcalay Myriam⁶⁷,Colombo Nicoletta⁴⁸,Tarella Corrado¹⁹

Affiliation:

1. Onco‐Hematology Division IEO, European Institute of Oncology IRCCS Milan Italy

2. Ospedale di Busto Arsizio, ASST Valle Olona Busto Arsizio Italy

3. Laboratory of Clinical Genomics IEO, European Institute of Oncology IRCCS Milan Italy

4. Department of Gynecology IEO, European Institute of Oncology IRCCS Milan Italy

5. Laboratory of Hematology‐Oncology IEO, European Institute of Oncology IRCCS Milan Italy

6. Department of Experimental Oncology European Institute of Oncology IRCCS Milan Italy

7. Department of Oncology and Hemato‐Oncology University of Milan Milan Italy

8. Gynecologic Cancer Program European Institute of Oncology IRCCS and University of Milan‐Bicocca Milan Italy

9. Department of Health Sciences University of Milan Milan Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34162

Reference37 articles.

1. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

2. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status

3. Integrated genomic analyses of ovarian carcinoma

4. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

5. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia;Cancer Reports;2024-08

3. Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045;International Journal of Cancer;2023-08-21

4. Post PARP inhibitor therapy-related acute megakaryoblastic leukemia in a patient with germline BRCA1-mutated high-grade serous ovarian carcinoma;Leukemia & Lymphoma;2023-05-19

5. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours;British Journal of Haematology;2023-03-23